COL12A1 (F4D4U) Rabbit mAb #36276
- WB
Supporting Data
| REACTIVITY | H M |
| SENSITIVITY | Endogenous |
| MW (kDa) | 333 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Background
Collagen type XII α1 chain (COL12A1), the largest member of the fibril-associated collagens with interrupted triple helix (FACIT) collagen family, contains fibronectin type III repeats, von Willebrand factor A domains, and two triple-helical domains (4). There are two major isoforms, a long form of 3063 amino acids and a short form of 1899 amino acids. COL12A1 binds to type I collagen fibrils and contributes to tissue biomechanics in the cornea, skeletal muscle, and tendon tissues (reviewed in 5). Mutations in the COL12A1 gene are correlated with myopathapies (6,7). COL12A1 expression is upregulated in several types of cancer; this elevation is thought to enhance tumor migration, invasiveness, and metastasis and, in some cases, correlates with poor prognosis (8-13).
- Barkan, D. et al. (2010) Eur J Cancer 46, 1181-8.
- Hynes, R.O. (2009) Science 326, 1216-9.
- Ricard-Blum, S. (2011) Cold Spring Harb Perspect Biol 3, a004978.
- Gerecke, D.R. et al. (1997) Genomics 41, 236-42.
- Chiquet, M. et al. (2014) Int J Biochem Cell Biol 53, 51-4.
- Hicks, D. et al. (2014) Hum Mol Genet 23, 2353-63.
- Zou, Y. et al. (2014) Hum Mol Genet 23, 2339-52.
- Yan, Y. et al. (2023) Endocr Relat Cancer 30, e230012. doi: 10.1530/ERC-23-0012.
- Papanicolaou, M. et al. (2022) Nat Commun 13, 4587.
- Jiang, X. et al. (2019) Mol Med Rep 20, 3103-3112.
- Wu, Y. and Xu, Y. (2020) Cancer Med 9, 4743-4755.
- Duan, S. et al. (2018) Mol Med Rep 18, 3727-3736.
- Karagiannis, G.S. et al. (2012) Oncotarget 3, 267-85.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.